Rockwell Medical Announces Poster Presentation and Oral Presentation on Triferic at the 7th Congress of the International Bio...
April 27 2017 - 8:30AM
Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated
biopharmaceutical company targeting end-stage renal disease (ESRD)
and chronic kidney disease (CKD) with innovative products for the
treatment of iron replacement, secondary hyperparathyroidism and
hemodialysis, announced today that a poster and oral presentation
for Triferic (ferric pyrophosphate citrate)have been selected by
the International BioIron Society (IBIS) and will be presented at
their 7th International Congress in Los Angeles, at UCLA, at the
Luskin Conference Center, on May 7 – 11, 2017. Triferic is the only
FDA approved therapy indicated to replace iron and maintain
hemoglobin in chronic kidney disease patients receiving
hemodialysis.
Presentation schedule at the BioIron meeting:
Poster Presentation:No. 70 Pharmacokinetics (Pk) Of Ferric
Pyrophosphate Citrate (Triferic): Modeling Diurnal Iron and
Additivity Of Triferic In Healthy Volunteers Iron Raymond Pratt,
MD¹, Mark Bush, PhD, Scott Brantley, PhD and Ajay Gupta, MD
Rockwell Medical, Inc., Wixom, MI, USA and Nuventra, Durham,
NCMonday, May, 8, 4:45-7:00PM PDT
Oral
Presentation:Ferric Pyrophosphate Citrate (Triferic), a Novel
Therapy that Treats Anemia of Inflammation and Overcomes Functional
Iron Deficiency.Ajay Gupta, MD and Raymond Pratt, MD Rockwell
Medical, Inc., Wixom, MI USAThursday, May 11, 3:00PM PDT
The BioIron Meeting is the main international forum
for the comprehensive presentation and discussion of cutting-edge
advances in the biology of iron and the role of iron in medical
science. The knowledge gained from these meetings has had a major
translational impact in traditional iron-related disorders such as
iron overload and deficiency. Furthermore, an essential role for
iron has been recognized in other common disorders, including
cancer, cardiovascular, inflammatory and neurodegenerative
disorders.
The most recent results and advances in the field
will be presented at the meeting. Oral presentations selected from
the submitted contributions will present novel unpublished data.
For these reasons and for its strong interdisciplinary character
the meeting provides a great opportunity to foster collaboration
among iron scientists and clinicians.
About TrifericTriferic is the only
FDA approved drug indicated to replace iron and maintain hemoglobin
in hemodialysis patients suffering from anemia. Via dialysate
during each dialysis treatment, Triferic replaces the 5-7 mg iron
loss that occurs in all patients, effectively maintaining their
iron balance. Unlike IV iron products, Triferic binds iron
immediately and completely to transferrin (carrier of iron in the
body) upon entering the blood and is then transported directly to
the bone marrow to be incorporated into hemoglobin, with no
increase in ferritin (stored iron and inflammation) and no
anaphylaxis, addressing a significant unmet need in overcoming
Functional Iron Deficiency (FID) in ESRD patients. Please visit
www.triferic.com to view the Triferic mode-of-action (MOA) video
and for more information.
About Rockwell MedicalRockwell
Medical is a fully-integrated biopharmaceutical company targeting
end-stage renal disease (ESRD) and chronic kidney disease (CKD)
with innovative products and services for the treatment of iron
replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell’s recent FDA approved drug
Triferic is indicated for iron replacement and maintenance of
hemoglobin in hemodialysis patients. Triferic delivers iron to
patients during their regular dialysis treatment, using dialysate
as the delivery mechanism. Triferic has demonstrated that it safely
and effectively delivers sufficient iron to the bone marrow and
maintains hemoglobin, without increasing iron stores (ferritin).
Rockwell intends to market Triferic to hemodialysis patients in the
U.S. dialysis market and globally.
Rockwell’s FDA approved generic drug Calcitriol is
for treating secondary hyperparathyroidism in dialysis patients.
Calcitriol (active vitamin D) injection is indicated in the
management of hypocalcemia in patients undergoing chronic renal
dialysis. It has been shown to significantly reduce elevated
parathyroid hormone levels. Reduction of PTH has been shown to
result in an improvement in renal osteodystrophy. Rockwell
intends to market Calcitriol to hemodialysis patients in the U.S.
dialysis market.
Rockwell is also an established manufacturer and
leader in delivering high-quality hemodialysis
concentrates/dialysates to dialysis providers and distributors in
the U.S. and abroad. As one of the two major suppliers in the U.S.,
Rockwell’s products are used to maintain human life by removing
toxins and replacing critical nutrients in the dialysis patient’s
bloodstream. Rockwell has three U.S. manufacturing/distribution
facilities.
Rockwell’s exclusive renal drug therapies support
disease management initiatives to improve the quality of life and
care of dialysis patients and are intended to deliver safe and
effective therapy, while decreasing drug administration costs and
improving patient convenience. Rockwell Medical is developing a
pipeline of drug therapies, including extensions of Triferic for
indications outside of hemodialysis. Please visit
www.rockwellmed.com for more information.
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws, including, but not limited to, Rockwell’s
intention to sell and market Calcitriol and Triferic. Words such as
“may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,”
“project,” “plan”, “intend” or similar expressions, or statements
regarding intent, belief, or current expectations, are
forward-looking statements. While Rockwell Medical believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in Rockwell Medical’s
SEC filings. Thus, actual results could be materially different.
Rockwell Medical expressly disclaims any obligation to update or
alter statements whether as a result of new information, future
events or otherwise, except as required by law.
Triferic® is a registered trademark of Rockwell
Medical, Inc.
Michael Rice, Investor Relations; 646-597-6979
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024